

- I      Neurological Disorders – Epidemiology, Clinical Overview,  
and Model Systems**
1. Stroke
  2. Parkinson's Disease
  3. Amyotrophic Lateral Sclerosis
  4. Alzheimer's Disease and Other Neurodegenerative Diseases
  5. CNS Inflammation
  6. Neurotrauma
  7. Spinal Cord Injury
- II     Cellular and Molecular Mechanisms**
8. Apoptosis and Necrosis
  9. Inflammation
  10. Metabolic Dysfunctions
  11. Protein Misfolding
  12. Axonal Growth Inhibition
  13. Neurogenesis
  14. Excitotoxicity
- III    Therapies**
15. Spinal Cord Trauma
  16. Neurodegeneration
  17. Perspectives for Neuroprotective Therapies in Basic Research  
and Clinical Application



## Contents

**Preface** V

**List of Contributors** XVII

- I Neurological Disorders – Epidemiology, Clinical Overview, and Model Systems**
- 1 Stroke** 1  
*Andreas Meisel, Konstantin Prass, Tilo Wolf, Ulrich Dirnagl*  
Abstract 1
- 1.1 Introduction 1
- 1.2 The Penumbra Concept 4
- 1.3 Excitotoxicity 5
- 1.4 Oxygen Free Radicals 5
- 1.5 Tissue Acidosis 6
- 1.6 Peri-infarct Depolarizations 7
- 1.7 Inflammation 8
- 1.8 Damage to the Blood–Brain-Barrier 10
- 1.9 Programmed Cell Death and Apoptosis 11
- 1.10 Ischemia-induced DNA Damage, DNA Repair, and p53 as Genotoxic Sensor 13
- 1.11 Epigenetics 15
- 1.12 Gene Expression 16
- 1.13 Cell Replacement 17
- 1.14 Endogenous Neuroprotection – Ischemic Tolerance 19
- 1.15 Stroke Induced Immune Depression (SIDS) 20
- 1.16 Conclusion 21
- References 22
- 2 Parkinson’s Disease** 29  
*Marina Romero-Ramos, Matthew Maingay and Deniz Kirik*
- 2.1 Epidemiology of Parkinson’s Disease 30
- 2.1.1 Genetic Contribution 30

2.1.2	Environmental Factors	31
2.2	Oxidative Stress In Parkinson's Disease	32
2.3	Role of Alpha-Synuclein in Parkinson's Disease	33
2.3.1	Alpha-Synuclein in Lewy Bodies	33
2.3.2	Alpha-Synuclein and Oxidative Stress	34
2.4	The Involvement of Proteasome in PD	36
2.4.1	Parkin Involvement in PD	37
2.5	Other Genes Involved in Familial Parkinson's Disease	39
2.6	Neurotoxic PD Models	39
2.6.1	Oxidative Stress	40
2.6.2	Dopamine Homeostasis/Complex I	40
2.6.3	Proteasome	41
2.7	Genetic Models of Parkinson's Disease	41
2.7.1	Alpha-Synuclein Overexpressing Transgenic Animals	41
2.7.2	Parkin-related Genetic Models	42
2.7.3	Viral Vectors for <i>In Vivo</i> Gene Transfer of Disease-related Proteins to the CNS	43
2.7.3.1	Local Overexpression of alpha-synuclein	43
2.7.3.2	Local Overexpression of Parkin-related Proteins	45
	Acknowledgements	45
	References	45
<b>3</b>	<b>Amyotrophic Lateral Sclerosis</b>	<b>49</b>
	<i>Georg Haase</i>	
3.1	Human Motor Neuron Diseases	49
3.1.1	Familial ALS Linked to SOD1 Mutations	50
3.1.2	Juvenile ALS Linked to Alsin Mutations	51
3.2	Cell Culture Models of Motoneuron Degeneration	51
3.2.1	Neuronal Cell Lines	51
3.2.2	Isolated Motoneuron Cultures	52
3.2.3	Organotypic Cultures	53
3.3	Animal Models of Motor Neuron Disease	53
3.3.1	Axotomy Models	54
3.3.2	Mutant SOD1 Mice	54
3.3.3	<i>p<sup>mn</sup></i> Mice	59
3.4	Future Neuroprotective Approaches	60
3.4.1	Axonal Protection	60
3.4.2	Mutant SOD1 Knockdown by RNA Interference	61
3.5	Conclusion	61
	References	61
<b>4</b>	<b>Alzheimer's Disease and Other Neurodegenerative Diseases</b>	<b>69</b>
	<i>Philipp J. Kahle and Christian Haass</i>	
	Abstract	69
4.1	Introduction	70

4.2	Transgenic Invertebrates	70
4.3	Transgenic Mice	71
4.3.1	Tyrosine Hydroxylase (TH) Promoter	71
4.3.2	Platelet-derived Growth Factor- $\beta$ (PDGF $\beta$ ) Promoter	72
4.3.3	Thy1 Promoter	72
4.3.4	Prion Protein (PrP) Promoter	73
4.3.5	Glial Expression	74
4.4	Viral Models	75
4.5	Conclusion and Outlook	76
	References	76
<b>5</b>	<b>CNS Inflammation</b>	<b>83</b>
	<i>Christine Stadelmann and Wolfgang Brück</i>	
5.1	Introduction	83
5.2	The Pathologic Characteristics of the MS Plaque	84
5.3	Axonal Pathology in MS	85
5.4	Neuronal Pathology in Multiple Sclerosis	86
5.5	Lessons from Animal Models	87
	References	88
<b>6</b>	<b>Neurotrauma</b>	<b>93</b>
	<i>Ibolja Cernak, Paul M. Leavitt, Alan I. Faden</i>	
6.1	Introduction	93
6.2	<i>In Vivo</i> Models	94
6.2.1	Static Brain Injury Models	95
6.2.2	Dynamic Brain Injury Models	95
6.2.2.1	Indirect Dynamic Brain Injury	95
6.2.2.2	Direct Dynamic Brain Injury	96
6.2.3	Combined Neurotrauma Models	104
6.3	<i>In Vitro</i> Models	104
6.3.1	Tension Stress-induced Injury	107
6.3.1.1	Stretch Injury Models	107
6.3.2	Compression Injury Models	108
6.3.2.1	Weight-drop Model	109
6.3.2.2	Hydrostatic Pressure Models	109
6.3.2.3	Fluid-percussion Models	109
6.3.3	Shear Injury Models	110
6.3.3.1	Acceleration Models	110
6.3.3.2	Hydrodynamic Model	110
6.3.3.3	Primary Axotomy/Transection Models	111
6.4	Conclusion	112
	References	113

<b>7</b>	<b>Spinal Cord Injury</b>	127
	<i>Poonam Verma and James W. Fawcett</i>	
7.1	Acute Neuroprotection (preventing neuronal death)	129
7.2	Regeneration of Nerve Fiber Tracts (initiating growth following injury)	130
7.2.1	Extrinsic Mechanisms	130
7.2.1.1	The Glial Scar	131
7.2.1.2	Blockage of Glial Scar Formation	131
7.2.1.3	Modification of Growth-inhibitory Molecules	132
7.2.1.4	Selective Removal of Astrocytes	134
7.2.2	Intrinsic Neuronal Control of Regeneration	134
7.2.2.1	Neuronal Age	135
7.2.2.2	Site of Transection	135
7.2.2.3	Neuronal Variability	136
7.3	Bridging Cysts and Scars and Cellular Replacement	136
7.4	Replacing Lost Neurons	137
7.4.1	Neural Transplantation	137
7.4.2	Replacing Lost Neurons from Stem Cells	138
7.5	Treating Demyelination	138
7.6	Enhancing Plasticity	139
7.7	Future Expectations	140
	References	141
<b>II</b>	<b>Cellular and Molecular Mechanisms</b>	
<b>8</b>	<b>Apoptosis and Necrosis</b>	149
	<i>Laura Korhonen and Dan Lindholm</i>	
8.1	Introduction	149
8.2	Apoptosis <i>versus</i> Necrosis	150
8.3	Genetics of Apoptosis and the Proteins Involved	151
8.3.1	<i>Caenorhabditis Elegans</i> as a Model System	151
8.3.2	Caspases	153
8.3.3	Anti-apoptotic Proteins	155
8.4	Cellular Mechanisms of Apoptosis	160
8.4.1	The Role of Mitochondria and the Apoptosome Complex	160
8.4.2	Cell Death in Neurodegenerative Diseases	162
	References	163
<b>9</b>	<b>Inflammation</b>	169
	<i>Harald Neumann</i>	
9.1	Introduction	169
9.2	Innate Immune Responses in the CNS	171
9.3	Dual Mechanism of Innate Immunity in the CNS	172
9.4	Antigen Presentation for Adaptive Immune Responses in the CNS	173
9.5	Regulation of Adaptive Immune Responses in the CNS	174

- 9.6 Immune Surveillance of the CNS by T Lymphocytes 176
- 9.7 Effector Mechanisms of Lymphocytes 177
- Acknowledgement 180
- References 183
- 10 Metabolic Dysfunctions 187**  
*Konstantin-A. Hossmann*
- 10.1 Introduction 187
- 10.2 Disturbances of the Energy Metabolism 188
- 10.2.1 Energy Production and Turnover 188
- 10.2.2 Reduction of Oxygen Supply 188
- 10.3 Disturbances of Flow-coupling 190
- 10.4 Mitochondrial Dysfunction 191
- 10.5 Importance of Disturbed Energy Metabolism for Injury Evolution 192
- 10.5.1 Global Brain Ischemia 192
- 10.5.2 Focal Brain Ischemia 194
- 10.5.3 Epileptic Seizures 196
- 10.5.4 Head Trauma 197
- 10.6 Disturbances of Protein Synthesis 198
- 10.6.1 Mechanisms of Disturbed Protein Synthesis 198
- 10.7 Importance of Disturbed Protein Synthesis on Injury Evolution 200
- 10.7.1 Global Brain Ischemia 200
- 10.7.2 Focal Ischemia 201
- 10.7.3 Epileptic Seizures 203
- 10.7.4 Head Trauma 203
- 10.8 Therapeutical Implications 204
- References 206
- 11 Protein Misfolding 209**  
*Milene Russelakis-Carneiro, Claudio Hetz, Joaquin Castilla and Claudio Soto*
- Abstract 209
- 11.1 Introduction 209
- 11.2 Disease Propagation by Replication of Prion Protein Misfolding 210
- 11.3 Prion Biology 211
- 11.4 Prion Pathogenesis 214
- 11.5 Neuronal Targeting 215
- 11.6 Neuronal Apoptosis in Prion Diseases 215
- 11.7 ER-Stress and Apoptosis in Prion Diseases 216
- 11.8 Concluding Remarks 219
- References 220
- 12 Axonal Growth Inhibition 225**  
*Anne D. Zurn and Christine E. Bandtlow*
- 12.1 Introduction 225
- 12.2 Intrinsic Properties of CNS Neurons 225

12.2.1	Survival of Injured Neurons	225
12.2.2	Developmental Loss of Regenerative Ability	226
12.2.3	Intrinsic Differences in Growth Potential	227
12.2.4	Transient Expression of Growth-associated Molecules	227
12.2.5	Conditioning Lesion	228
12.3	Extrinsic Factors: The CNS as A Non-conductive Growth Environment	229
12.3.1	Cellular Components of Inhibition	229
12.3.1.1	The Glial Scar	229
12.3.1.2	Oligodendrocytes and Myelin (Wallerian Degeneration)	230
12.3.1.3	Secondary Injury: Inflammation, Cell-mediated Immunity, and Glial Cell Loss	231
12.3.1.4	Genetic Influences on Cellular Reactions to CNS Injury	232
12.3.2	Molecular Components of Inhibition	232
12.3.2.1	Axon growth Inhibitors in the Glial Scar	232
12.3.2.2	Myelin-associated Growth Inhibitors	235
12.3.3	Transduction of Axon Growth-inhibitory Signals	238
12.3.3.1	Receptors for Myelin-associated Inhibitors	238
12.3.3.2	Signaling Pathways of Myelin-associated Inhibitors	239
12.4	Experimental Strategies to Overcome Growth Inhibition	241
12.5	Conclusion	243
	References	244
<b>13</b>	<b>Neurogenesis</b>	<b>257</b>
	<i>Sebastian Jessberger and Gerd Kempermann</i>	
13.1	Introduction	257
13.2	Neural Stem- and Precursor Cells in the Adult Brain	259
13.2.1	Neural Stem Cells in the Adult Brain: <i>In vitro</i>	259
13.2.2	Neural Stem Cells In The Adult Brain: <i>In vivo</i>	260
13.3	Maturation and Migration of Adult-generated Neurons in the Adult Brain	262
13.4	Neurogenesis in the Adult Brain – Age Dependency, Persistence and Genetic Determinants	265
13.4.1	Neurogenesis in Aged Animals	265
13.4.2	Long-term Persistence of Adult-generated Neurons in the SVZ and Hippocampus	265
13.4.3	Genetic Influence on Adult Hippocampal Neurogenesis	266
13.5	Regulation of Adult Neurogenesis	266
13.5.1	Learning	267
13.5.2	Environmental Enrichment	267
13.5.3	Physical Activity	268
13.5.4	Stress and Depression	269
13.5.5	Epilepsy	270
13.5.6	Ischemia and Cortical Trauma	271
13.6	Possible Functional Relevance of Neurogenesis in the Adult Brain	272
13.7	Therapeutic Strategies for Neural Cell Replacement	274

13.7.1	Endogenous Neurogenesis	274
13.7.2	Transplantation of Stem- or Precursor Cells into the Damaged Brain	274
	Acknowledgements	276
	References	276
<b>14</b>	<b>Excitotoxicity</b>	<b>287</b>
	<i>Stuart A. Lipton, MD, PhD</i>	
	Abstract	287
14.1	Introduction	288
14.2	The Search for Clinically-Tolerated NMDA Receptor Antagonists	289
14.3	Excitotoxicity	290
14.3.1	Definition and Clinical Relevance	290
14.3.2	Links between Stroke and Vascular Dementia to Excitotoxic Damage	291
14.3.2.1	Possible Links between Excitotoxic Damage and Alzheimer's Disease	292
14.3.3	Pathophysiology of Excitotoxicity: Role of the NMDA Receptor	292
14.3.3.1	The Importance of Off-Rate from Channel Block	295
14.4	Memantine	296
14.4.1	Background and Pharmacology: Uncompetitive Open-channel Block	296
14.4.2	Voltage Dependence, Partial Trapping, and Other Possible Effects of Memantine	299
14.4.3	Neuroprotective Efficacy	300
14.5	NitroMemantines	302
14.6	Summary	303
	Acknowledgments	304
	Appendix	304
	References	305
<b>III</b>	<b>Therapies</b>	
<b>15</b>	<b>Spinal Cord Trauma</b>	<b>311</b>
	<i>V. Dietz</i>	
	Abstract	311
15.1	Epidemiology	312
15.2	Clinical Aspects	312
15.2.1	Acute Stage	312
15.2.2	Dysfunction of the Autonomic Nervous System	313
15.2.3	The Evolution of Signs and Symptoms	314
15.3	Principles of Therapy	315
15.3.1	General Concepts	315
15.3.2	Transition from Acute Care to Rehabilitation	316
15.3.3	Basic Aspects of Motor Rehabilitation: Neuronal Activity of the Isolated Spinal Cord	316
15.4	Current Approaches in Motor Rehabilitation	317
15.4.1	Spinal Reflex Plasticity	318
15.4.2	Use-Dependent Plasticity – Rehabilitative Approaches	318

15.4.3	Task-specific Plasticity	319
15.4.4	Effects of Locomotor Training in Spinal Cord Injury	319
15.5	Search for Reliable Clinical Assessment	321
15.5.1	Physical Signs and Function	321
15.5.2	Appropriate Assessment of Function – Basis for New Interventional Therapies	322
15.6	Conclusion	324
	References	325
<b>16</b>	<b>Neurodegeneration</b>	<b>329</b>
	<i>Jörg B. Schulz, MD</i>	
16.1	What Is Neuroprotection?	329
16.2	Outcome Measures in Clinical Studies	330
16.3	Specific Diseases	331
16.3.1	Wilson's Disease	331
16.3.2	Parkinson's Disease	332
16.3.2.1	DATATOP Study	332
16.3.2.2	Dopamine Agonists	332
16.3.2.3	Anti-Excitotoxic Treatment	333
16.3.2.4	Neurotrophins	333
16.3.2.5	MAP Kinase Inhibitors	334
16.3.2.6	Transplantation	334
16.3.2.7	Deep Brain Stimulation	335
16.3.2.8	Coenzyme Q <sub>10</sub>	335
16.3.3	Multiple System Atrophy and Progressive Supranuclear Palsy	335
16.3.4	Alzheimer's Disease	336
16.3.4.1	Symptomatic Treatment	336
16.3.4.2	Antioxidants	337
16.3.4.3	Anti-inflammatory Approaches	337
16.3.4.4	Estrogen Replacement	337
16.3.4.5	NMDA Receptor Antagonists	338
16.3.4.6	Experimental Therapies	338
16.3.4.7	Immunization	338
16.3.4.8	Cholesterol-lowering Therapy	340
16.3.5	Huntington's Disease	341
16.4	Why Do So Many Clinical Studies Fail? What Do We Need?	342
	References	343
<b>17</b>	<b>Perspectives for Neuroprotective Therapies in Basic Research and Clinical Application</b>	<b>351</b>
	<i>Mathias Bähr and Pawel Kermer</i>	
	References	354
	<b>Index</b>	<b>361</b>